BBR 3409

Drug Profile

BBR 3409

Latest Information Update: 07 Mar 2007

Price : $50

At a glance

  • Originator Roche; University of Vermont
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 07 Mar 2007 Discontinued - Preclinical for Cancer in Italy (unspecified route)
  • 14 Feb 2001 No-Development-Reported for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top